GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA

Summary

An investigator-initiated double-blind, parallel-group randomised controlled trial of Methotrexate versus GOLimumab and Methotrexate in very early PsA using clinical and whole body MRI outcomes.

Timeline

Start

2015-10-27

Primary completion

2023-07

Completion

2023-07

Publications

• De Marco G, Maksymowych WP, Ostergaard M, Eshed I, Tan AL, Helliwell PS, McGonagle D, Hensor EMA, Marzo-Ortega H. Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naive, active PsA: data from the GOLMePsA clinical trial. Rheumatology (Oxford). 2026 Jun 30;65(7):keag308. doi: 10.1093/rheumatology/keag308.

Drugs

Indications